WA-SPIE
29.1.2024 20:25:27 CET | Business Wire | Press release
SPIE, the international society for optics and photonics, and The University of Manchester announced the establishment of the SPIE-Manchester Postgraduate Scholarship in Photonics, today during SPIE Photonics West in San Francisco. The $500,000 gift from SPIE will be matched 100% by the University. Part of the SPIE Endowment Matching Program, this new endowment will support both early-career researchers and returning researchers at the University’s Photon Science Institute in partnership with the Royce Institute, the UK’s national institute for advanced materials research and innovation. This is the 11th major SPIE gift to universities and institutes as part of the Society's ongoing program to support the expansion of optical engineering teaching and research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240126857659/en/
Doctoral students at work in the Photon Science Institute lab. (Photo: Business Wire)
With a goal of increasing diversity in optics and photonics, the SPIE-Manchester Postgraduate Scholarship will have a particular focus on funding individuals returning to research following a career break or time in industry, and those pursuing unconventional career pathways or part-time study (situations often necessitated by caring responsibilities, for example). Aligning current research and industrial needs for a robust training pipeline, an additional unique feature of the scholarship is an optional final-year placement of up to 12 months, during which students can develop industry-relevant skills in collaboration with local optics and photonics companies.
“Today marks just the beginning of the partnership between The University of Manchester and SPIE,” noted Department Head of Research for Physics and Astronomy at The University of Manchester Dr. Patrick Parkinson. “The establishment of the SPIE-Manchester Postgraduate Scholarship in Photonics is a testament to our shared values within skills training, fostering diversity in education and the vital role of photonics. This announcement holds special significance as it coincides with the University’s bicentenary year. We take great pride in using this generous donation to not only advance research and education, but also to solidify our existing partnerships and forge new industrial collaborations to deliver a doctoral training program that will ensure a sustainable workforce for the North West of England.”
“Our expanding field needs researchers and engineers, though for some who might be interested in a photonics career, traditional educational paths are barriers to their success,” said SPIE CEO Kent Rochford. “The SPIE-Manchester Postgraduate Scholarship in Photonics aims to remove those barriers and provide exciting opportunities for early-career researchers and those who may be pursuing unconventional career paths. Working internally at the university’s Photon Science Institute with the option of an industry-focused placement, promises to benefit young researchers, as well as our future diverse workforce. I very much look forward to meeting the leaders in optics and photonics technologies who will emerge from this dynamic partnership between SPIE and The University of Manchester.”
The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics. With this latest gift, SPIE has provided over $4 million in matching gifts, resulting in more than $11 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college, institute, and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.
About the University of Manchester
The University of Manchester is a member of the prestigious Russell Group and one of the UK’s largest single-site universities. We have over 40,000 students, 12,000 staff and, with 500,000 former students from more than 190 countries, are home to the largest alumni community of any campus-based university in the UK. We are ranked in the top ten of the Times Higher Education (THE) Impact Rankings globally; are the top UK University for graduate employability according to The Graduate Market in 2022 and no fewer than 25 Nobel laureates have either worked or studied here. Manchester was also named 5th place for research power — the quality and scale of research and impact — in the UK government’s (REF) 2021. Visit www.manchester.ac.uk for further information or https://www.manchester.ac.uk/discover/vision/ for our latest strategic vision.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240126857659/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes12.5.2026 08:00:00 CEST | Press release
Merz Therapeutics to present 11 abstracts at ISPRM World Congress 2026, highlighting its commitment to improving outcomes for people living with movement disorders Updated analysis indicates that optimizing botulinum toxin dosing over multiple injection cycles may be an important factor in improving outcomes in people living with limb spasticity, with available clinical data suggesting support for flexible, individualized dosing with incobotulinumtoxinA (XEOMIN®) Updated meta-analyses examining secondary treatment failure and neutralizing antibodies suggest a potential for sustained long-term treatment response with incobotulinumtoxinA (XEOMIN®) Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced it will present 11 scientific abstracts at the International Society of Physical and Rehabilitation Medicine (ISPRM) 2026 World Congress. Taking place from May 17th to May 21st in Vancouver, Canada, the presentations will feature key data on optimal dosin
SES Delivers Robust Q1 2026 Results & Reiterates Full-Year Outlook12.5.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2026. Q1 2026 Performance (€ million) Q1 2026 as reported (1) Q1 2025 as reported (1) ∆ At constant FX (2) Q1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.18 1.04 1.04 Revenue 847 509 +80.5% 909 +3.1% Adjusted EBITDA (4) 404 280 +57.0% 425 +5.0% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralise currency variations 3) ‘Like-for-like basis’ is as if Intelsat fully consolidated from 1 January 2024 4) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +106.0% yoy(1) supported by growth in Mobility (+207.8% yoy(1); including positive impact from a contract restructuring in Aviation) and Gov
GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI12.5.2026 03:00:00 CEST | Press release
GIGABYTE Technology, a global leader in high-performance computing, is taking its most comprehensive end-to-end portfolio for AI infrastructure to COMPUTEX 2026 under the theme "Future Landing." As AI transitions from training into large-scale inference and real-world operation, GIGABYTE addresses the industry's most pressing challenge: not whether AI can be built, but how quickly and reliably it can be deployed, operated, and sustained at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299592/en/ GIGABYTE Unveils “Future Landing” at COMPUTEX 2026 as Implementation Becomes Critical to Scaling AI At COMPUTEX, GIGABYTE organizes its showcase around three states that define the lifecycle of production AI infrastructure. Ready: integrated systems that have been fully built, simulated, validated, and prepared for deployment. Deployable: modular clusters engineered for rapid implementation across diverse environments.
INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering11.5.2026 21:49:00 CEST | Press release
INNIO Group ("INNIO"), a leading global distributed energy solutions provider, today announces that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511389675/en/ INNIO Group Announces Filing of Registration Statement for Proposed Initial Public Offering The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined. INNIO has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "INIO." Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. BofA Securities, Barclays and Citigroup are acting as book-running managers for the proposed offering. Baird, BNP Paribas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom